Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma

Qiuping Chen; Quan Sun; Jing Zhang; Baixue Li; Quansheng Feng; Jibin Liu

doi:10.1371/journal.pone.0295090

Loading metrics

Open Access

Peer-reviewed

Research Article

Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma

Qiuping Chen ,

Contributed equally to this work with: Qiuping Chen, Quan Sun

Roles Data curation, Formal analysis, Resources, Software, Writing – original draft, Writing – review & editing

Affiliation College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China

https://orcid.org/0000-0002-7188-8989

⨯
Quan Sun ,

Contributed equally to this work with: Qiuping Chen, Quan Sun

Roles Data curation, Methodology, Resources, Software

Affiliation Guangzhou ZhongWei Public Health Technology Accessment Institute, Guangzhou, China
⨯
Jing Zhang ,

Roles Data curation

¶‡ These authors also contributed equally to this work.

Affiliation College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
⨯
Baixue Li ,

Roles Conceptualization, Funding acquisition, Supervision

* E-mail: fengqs118@163.com (QF); baixuelee@163.com (BL); eaeas12@163.com (JL)

¶‡ These authors also contributed equally to this work.

Affiliation College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
⨯
Quansheng Feng ,

Roles Conceptualization, Data curation, Funding acquisition, Methodology, Project administration, Resources, Supervision

* E-mail: fengqs118@163.com (QF); baixuelee@163.com (BL); eaeas12@163.com (JL)

¶‡ These authors also contributed equally to this work.

Affiliation College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China

https://orcid.org/0000-0003-3437-8987

⨯
Jibin Liu

Roles Conceptualization, Project administration, Supervision

* E-mail: fengqs118@163.com (QF); baixuelee@163.com (BL); eaeas12@163.com (JL)

¶‡ These authors also contributed equally to this work.

Affiliation College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
⨯

Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma

Qiuping Chen,
Quan Sun,
Jing Zhang,
Baixue Li,
Quansheng Feng,
Jibin Liu

Published: March 4, 2024
https://doi.org/10.1371/journal.pone.0295090

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Hepatocellular carcinoma
Is the Subject Area "Hepatocellular carcinoma" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Economics
Is the Subject Area "Economics" applicable to this article?

Thanks for your feedback.
Body weight
Is the Subject Area "Body weight" applicable to this article?

Thanks for your feedback.
Health economics
Is the Subject Area "Health economics" applicable to this article?

Thanks for your feedback.
Pharmacoeconomics
Is the Subject Area "Pharmacoeconomics" applicable to this article?

Thanks for your feedback.
Platelets
Is the Subject Area "Platelets" applicable to this article?

Thanks for your feedback.